Payers have taken a cautious approach to handling rising demand for the pricey new class of drugs known as glucagon-like peptide agnostics, or GLP-1s.
from Section Page News - Modern Healthcare https://ift.tt/1AXs5eW
Tuesday, May 16, 2023
Insurers, PBMs restrict access to weight loss drugs as demand soarsInsurers, PBMs restrict access to weight loss drugs as demand soarsInsurers, PBMs restrict access to weight loss drugs as demand soars
Insurers, PBMs restrict access to weight loss drugs as demand soars
from Section Page News - Modern Healthcare https://ift.tt/1AXs5eW
from Section Page News - Modern Healthcare https://ift.tt/1AXs5eW
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment